Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells.,Clinical & Translational Immunology

当前位置： X-MOL 学术 › Clin. Transl. Immunol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Enhancing chimeric antigen receptor T-cell immunotherapy against cancer using a nanoemulsion-based vaccine targeting cross-presenting dendritic cells.
Clinical & Translational Immunology ( IF 4.6 ) Pub Date : 2020-07-22 , DOI: 10.1002/cti2.1157
Jack D Chan _{1,

2} , Bianca von Scheidt ₁ , Bijun Zeng ₃ , Amanda J Oliver _{1,

2} , Ashleigh S Davey ₁ , Aesha I Ali _{1,

2} , Ranjeny Thomas ₃ , Joseph A Trapani _{1,

2} , Phillip K Darcy _{1,

2} , Michael H Kershaw _{1,

2} , Riccardo Dolcetti ₃ , Clare Y Slaney _{1,

2}

Affiliation

Adoptive transfer of chimeric antigen receptor (CAR)‐modified T cells is a form of cancer immunotherapy that has achieved remarkable efficacy in patients with some haematological cancers. However, challenges remain in CAR T‐cell treatment of solid tumours because of tumour‐mediated immunosuppression.

中文翻译：